Treatment with the investigational interleukin-6 inhibitor pacibekitug was associated with large, sustained decreases in high ...
Results from the Phase 2 TRANQUILITY trial showed that pacibekitug, an investigational monoclonal antibody targeting ...
The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.
The outcome of ZEUS will not impact Novo Nordisk’s previously communicated adjusted operating profit outlook for 2026 but will result in a non-cash impairment charge in Q3 2026. Full results of the ...
A protein called human resistin may help flip on one of the immune system’s most powerful inflammatory switches. Researchers ...
After the failure of Novo Nordisk’s IL-6 inhibitor ziltivekimab sent waves through the industry, the company has terminated ...
Inflammation is a symptom that your patients may have questions about. You’re likely to start by explaining how inflammation could be the result of infection or an injury. Chronic inflammation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results